Gainers

• Xenetic Biosciences (NASDAQ:XBIO) stock rose 10.2% to $2.8 during Wednesday's after-market session. The market value of their outstanding shares is at $5.8 million. As per the press release, Q3 earnings came out 4 days ago.
• VolitionRX (AMEX:VNRX) shares increased by 9.34% to $0.36. The market value of their outstanding shares is at $42.9 million. As per the news, the Q3 earnings report came out 4 days ago.
• Enveric Biosciences (NASDAQ:ENVB) stock moved upwards by 8.73% to $6.35. The company's market cap stands at $2.9 million. The company's, Q3 earnings came out 3 days ago.
• Dermata Therapeutics (NASDAQ:DRMA) shares rose 7.37% to $2.62. The company's market cap stands at $1.8 million. The company's, Q3 earnings came out 3 days ago.
• Streamex (NASDAQ:STEX) shares increased by 4.91% to $3.95. The market value of their outstanding shares is at $146.0 million. As per the news, the Q3 earnings report came out 3 days ago.
• FibroBiologics (NASDAQ:FBLG) shares moved upwards by 4.47% to $0.36. The market value of their outstanding shares is at $16.9 million.

Losers

• BioRestorative Therapies (NASDAQ:BRTX) stock decreased by 13.3% to $1.24 during Wednesday's after-market session. The company's market cap stands at $11.0 million.
• BioLine Rx (NASDAQ:BLRX) stock declined by 5.71% to $3.14. The market value of their outstanding shares is at $11.9 million.
• Lunai Bioworks (NASDAQ:LNAI) shares decreased by 4.01% to $1.44. The company's market cap stands at $27.1 million. The company's, Q1 earnings came out 3 days ago.
• Connect Biopharma Hldgs (NASDAQ:CNTB) shares declined by 3.81% to $3.03. The company's market cap stands at $143.6 million.
• Impact BioMedical (AMEX:IBO) stock declined by 3.65% to $0.42. The company's market cap stands at $5.3 million.
• Wellgistics Health (NASDAQ:WGRX) shares decreased by 3.22% to $0.56. The market value of their outstanding shares is at $58.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.